Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00036088
First received: May 7, 2002
Last updated: July 18, 2006
Last verified: July 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: Olanzapine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Eli Lilly and Company:
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion:
- You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
- You must have been diagnosed with schizophrenia
- You must be able to visit the doctor's office as scheduled for the next 7 months
Exclusion:
- You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
- You are either pregnant or breastfeeding
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036088
Hide Study Locations
Hide Study LocationsLocations
| United States, California | |
| El Centro, California, United States | |
| Glendale, California, United States | |
| Sherman Oaks, California, United States | |
| United States, Connecticut | |
| Middleton, Connecticut, United States | |
| Norwich, Connecticut, United States | |
| United States, Florida | |
| Melbourne, Florida, United States | |
| Miami, Florida, United States | |
| United States, Georgia | |
| Atlanta, Georgia, United States | |
| United States, Illinois | |
| Chicago, Illinois, United States | |
| Hoffman Estates, Illinois, United States | |
| United States, Indiana | |
| Lafayette, Indiana, United States | |
| United States, Maryland | |
| Rockville, Maryland, United States | |
| United States, Massachusetts | |
| Newton, Massachusetts, United States | |
| United States, Missouri | |
| St Charles, Missouri, United States | |
| United States, New York | |
| New York, New York, United States | |
| Olean, New York, United States | |
| Staten Island, New York, United States | |
| United States, Ohio | |
| Cincinnati, Ohio, United States | |
| United States, Oregon | |
| Portland, Oregon, United States | |
| United States, Pennsylvania | |
| Philadelphia, Pennsylvania, United States | |
| United States, Texas | |
| Austin, Texas, United States | |
| El Paso, Texas, United States | |
| Houston, Texas, United States | |
| Terrell, Texas, United States | |
| United States, Virginia | |
| Richmond, Virginia, United States | |
| Argentina | |
| La Plata, Buenos Aires, Argentina | |
| Godoy Cruz, Mendoza, Argentina | |
| Buenos Aires, Argentina | |
| Ciudad De Buenos Air, Argentina | |
| Austria | |
| Graz, Austria | |
| Innsbruck, Austria | |
| Linz, Austria | |
| Wein, Austria | |
| Wels, Austria | |
| Brazil | |
| Salvador, Bahia, Brazil | |
| Aparecida De Goiania, Goias, Brazil | |
| Pelotas, RS, Brazil | |
| Rio De Janeiro, Brazil | |
| Sau Paulo, Brazil | |
| Germany | |
| Essen, Germany | |
| Hamburg, Germany | |
| Tubingen, Germany | |
| Ireland | |
| Dublin, Ireland | |
| Mexico | |
| Mexico City, Mexico | |
| Peru | |
| Lima, Peru | |
| Puerto Rico | |
| Cidra, Puerto Rico | |
| Ponce, Puerto Rico | |
| Rio Piedras, Puerto Rico | |
| San Juan, Puerto Rico | |
| Spain | |
| Sama De Langreo, Asturias, Spain | |
| San Boi De Llobregat, Barcelona, Spain | |
| Elizondo, Navarra, Spain | |
| Pamplona, Navarra, Spain | |
| Barcelona, Spain | |
| United Kingdom | |
| Camberwell, London, United Kingdom | |
| Kings Lynn, Norfolk, United Kingdom | |
| Paisley, Scotland, United Kingdom | |
| Guildford, Surrey, United Kingdom | |
| London, United Kingdom | |
| Venezuela | |
| Caracas, Venezuela | |
Sponsors and Collaborators
Eli Lilly and Company
More Information
No publications provided by Eli Lilly and Company
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00036088 History of Changes |
| Other Study ID Numbers: | 2347, F1D-MC-HGHJ |
| Study First Received: | May 7, 2002 |
| Last Updated: | July 18, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Olanzapine Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents |
ClinicalTrials.gov processed this record on May 23, 2013